Work, practice, expense and liability relative value units (RVUs) are updated annually through the Centers for Medicare and Medicaid Services' Medicare Physician Fee Schedule (PFS) rulemaking. In ...

In this week’s View, Dr. Eagle looks at the 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis. He then discusses sex differences in ...

The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...

We want to hear from you. Complete a feedback survey here or leave a comment on the app's iTunes or Google Play page. Use the updated AnticoagEvaluator to make informed decisions on initiation of ...

Chronic consumption of high levels of caffeine a day can lead to an increase in high heart rate and blood pressure that persists after resting from a step test, increasing the risk of cardiovascular ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...

In this week’s View, Dr. Eagle looks at what adult cardiologists should know about congenital heart disease patients. He then discusses sudden cardiac arrest and death in competitive and recreational ...

In this interview, Clyde W. Yancy, MD, MACC, and Alison L. Bailey, MD FACC, discuss the Top Heart Failure Takeaways from 2024. Dr. Yancy discusses the FINEARTS-HF trial, the PREVENT calculator, the ...

Hypertension remains the leading global cause of death and disability, with more than half of hypertensive individuals in the U.S. failing to meet guideline-directed blood pressure (BP) targets. This ...

Global death counts due to cardiovascular disease (CVD) increased from 12.4 million in 1990 to 19.8 million in 2022, reflecting global population growth and aging and the contributions from ...

The U.S. Food and Drug Administration (FDA) has issued a safety communication noting the potential need for early device replacement of Boston Scientific Corporation Accolade pacemaker devices.

A State-of-the-Art review published in JACC: Cardiovascular Interventions covers the epidemiology, clinical implications, risk factors and preventive strategies for new-onset conduction disturbances ...